Cargando…

S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT)

BACKGROUND: Patients with schizophrenia often display three main types of symptoms: positive symptoms (e.g. auditory hallucinations or delusions), negative symptoms (e.g. blunted affect, lack or decline in speech, social withdrawal) and cognitive symptoms (e.g. impairment of working memory and decla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roeh, Astrid, Leucht, Stefan, Falkai, Peter, Langguth, Berthold, Papazova, Irina, Hasan, Alkomiet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888902/ http://dx.doi.org/10.1093/schbul/sby018.834

Ejemplares similares

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial
por: Hasan, Alkomiet, et al.
Publicado: (2020)

Personality Traits in Marathon Runners and Sedentary Controls With MMPI-2-RF
por: Roeh, Astrid, et al.
Publicado: (2020)

S79. ENHANCING WORKING MEMORY IN SCHIZOPHRENIA USING 1MA AND 2MA TRANSCRANIAL DIRECT STIMULATION TO THE LEFT DORSOLATERAL PREFRONTAL CORTEX
por: Papazova, Irina, et al.
Publicado: (2018)

Spironolactone alleviates schizophrenia-related reversal learning in Tcf4 transgenic mice subjected to social defeat
por: Stephan, Marius, et al.
Publicado: (2022)

Fitness is positively associated with hippocampal formation subfield volumes in schizophrenia: a multiparametric magnetic resonance imaging study
por: Maurus, Isabel, et al.
Publicado: (2022)

T54. EFFECTS OF GAMMA TRANSCRANIAL ALTERNATING CURRENT STIMULATION TO THE LEFT DORSOLATERAL PREFRONTAL CORTEX ON WORKING MEMORY IN SCHIZOPHRENIA PATIENTS
por: Papazova, Irina, et al.
Publicado: (2020)

Decreased Serum Brain-Derived Neurotrophic Factor Concentrations 72 Hours Following Marathon Running
por: Roeh, Astrid, et al.
Publicado: (2021)

S177. FRONTAL CORTICAL PLASTICITY IN SCHIZOPHRENIA PATIENTS EXAMINED BY LTP-INDUCING ANODAL TDCS AND REPETITIVE EEG
por: Pross, Benjamin, et al.
Publicado: (2018)

Anodal transcranial direct current stimulation sustainably increases EEG alpha activity in patients with schizophrenia
por: Pross, Benjamin, et al.
Publicado: (2022)

S192. EFFECTS OF NICOTINE INTAKE ON NEUROPLASTICITY IN SMOKING AND NON-SMOKING PATIENTS WITH SCHIZOPHRENIA
por: Pross, Benjamin, et al.
Publicado: (2020)

Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?
por: Roeh, Astrid, et al.
Publicado: (2019)

Nonpharmacological treatment of dyscognition in schizophrenia: effects  of aerobic exercise 
por: Maurus, Isabel, et al.
Publicado: (2019)

Schizophrenia as a disorder of disconnectivity
por: Schmitt, Andrea, et al.
Publicado: (2011)

S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS – RESULTS FROM AN EXPLORATORY RE-ANALYSIS
por: Hansbauer, Maximilian, et al.
Publicado: (2018)

11.3 CLINICAL AND NEUROBIOLOGICAL EFFECTS OF A CONTINUOUS AEROBIC ENDURANCE TRAINING IN MULTI-EPISODE SCHIZOPHRENIA PATIENTS
por: Malchow, Berend, et al.
Publicado: (2018)

F107. CSF ABNORMALITIES IN SCHIZOPHRENIA AND DEPRESSION: PRELIMINARY RESULTS FROM A LARGE SCALE COHORT
por: Salcedo, Tatiana Oviedo, et al.
Publicado: (2018)

Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial
por: Maurus, Isabel, et al.
Publicado: (2020)

High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon
por: Schoenfeld, Julia, et al.
Publicado: (2023)

Correction to: Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial
por: Maurus, Isabel, et al.
Publicado: (2021)

Association between aerobic fitness and the functional connectome in patients with schizophrenia
por: Roell, Lukas, et al.
Publicado: (2022)

Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review
por: Kirchner, Sophie K., et al.
Publicado: (2018)

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
por: Wagner, Elias, et al.
Publicado: (2021)

Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial
por: Strube, Wolfgang, et al.
Publicado: (2022)

Subjective burden and perspectives of German healthcare workers during the COVID-19 pandemic
por: Kramer, Victoria, et al.
Publicado: (2020)

Erkennen und behandeln von Antipsychotika-Nebenwirkungen
por: Hasan, Alkomiet, et al.
Publicado: (2022)

Associations between aerobic fitness, negative symptoms, cognitive deficits and brain structure in schizophrenia—a cross-sectional study
por: Maurus, Isabel, et al.
Publicado: (2022)

O7.4. SYSTEMATIC REVIEW, META-ANALYSIS AND META-REGRESSION OF PREDICTORS OF PLACEBO RESPONSE IN ACUTE SCHIZOPHRENIA
por: Leucht, Claudia, et al.
Publicado: (2018)

Psychiatric medication and physical performance parameters – Are there implications for treatment?
por: Hirschbeck, Anna, et al.
Publicado: (2022)

Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia
por: Yamada, Shinichi, et al.
Publicado: (2021)

Guideline for schizophrenia: implementation status and attitude toward an upcoming living guideline
por: Khorikian-Ghazari, Naiiri, et al.
Publicado: (2023)

F214. PSYCHOLOGICAL INTERVENTIONS FOR POSITIVE SYMPTOMS IN SCHIZOPHRENIA: A NETWORK META-ANALYSIS
por: Bighelli, Irene, et al.
Publicado: (2018)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

T47. IS THERE A DIURNAL VARIATION IN PSYCHIATRIC SYMPTOMS IN SCHIZOPHRENIA?
por: Daniel, David, et al.
Publicado: (2018)

Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice
por: Wehr, Michael C, et al.
Publicado: (2017)

Parameter-Based Evaluation of Attentional Impairments in Schizophrenia and Their Modulation by Prefrontal Transcranial Direct Current Stimulation
por: Gögler, Nadine, et al.
Publicado: (2017)

Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence
por: Malchow, Berend, et al.
Publicado: (2012)

S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects
por: Heilbronner, Urs, et al.
Publicado: (2016)

Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia
por: Trossbach, Svenja V., et al.
Publicado: (2019)

Improvement of conventional perception in stable patients with schizophrenia by add-on treatment with ipidacrine
por: Morozova, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0nl8sotpj8uivps0bdutjbkp4f